ALNY vs INCY: which stock is the better value?

A comparison of Alnylam Pharmaceuticals and Incyte Corporation reveals interesting insights into their valuations.

In the competitive landscape of pharmaceuticals, biotechnology, and life sciences, investors often seek value opportunities. Here, we compare Alnylam Pharmaceuticals Inc (ALNY) and Incyte Corporation (INCY) to see which stock offers a more attractive valuation based on key financial metrics.

Investor takeaway: While Incyte seems cheaper based on P/E, PEG, and P/B ratios, this doesn’t automatically mean it’s the better investment. Each company's unique circumstances and growth prospects should be considered.

Valuation Metrics Comparison

Incyte Corporation appears cheaper on most P/E, PEG, and P/B ratios, but this doesn’t necessarily make it the better investment overall.

Valuation Metrics Overview

When comparing Alnylam Pharmaceuticals and Incyte Corporation, we see distinct differences in their valuation metrics. Alnylam has a P/E ratio of 37.7, a PEG ratio of 0.32, and a P/B ratio of 22.17. In contrast, Incyte's P/E stands at 13.8, its PEG at 10.82, and its P/B at 3.53. These figures suggest that Incyte may be a more affordable option for investors looking at traditional valuation metrics.

Market Position and Analyst Consensus

Both companies operate within the same industry group and have received a 'Buy' consensus from analysts. Alnylam's market cap is US$29.9 billion, with an analyst target of US$370.55, indicating strong growth potential. Meanwhile, Incyte's market cap is US$22.0 billion, with an analyst target of US$129.13. This highlights that while Incyte appears cheaper, Alnylam's higher market cap and analyst target suggest a different growth trajectory.